Health Care [ 9/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases.
The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer.
Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in EmeryVille, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 11, 25 | -0.55 Decreased by -7.84% | -0.80 Increased by +31.25% |
| Aug 12, 25 | -0.54 Decreased by -86.21% | -0.72 Increased by +25.00% |
| May 14, 25 | -0.68 Increased by +42.86% | -0.75 Increased by +9.33% |
| Mar 17, 25 | -0.37 Increased by +28.14% | -0.77 Increased by +51.95% |
| Nov 14, 24 | -0.51 | -0.75 Increased by +32.00% |
| Aug 15, 24 | -0.29 | -0.70 Increased by +58.57% |
| May 14, 24 | -1.19 | -0.78 Decreased by -52.56% |
| Mar 27, 24 | -0.51 | -2.04 Increased by +74.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 8.66 M Decreased by -24.80% | -20.39 M Decreased by -8.63% | Decreased by -235.51% Decreased by -44.45% |
| Jun 30, 25 | 8.51 M Decreased by -57.45% | -19.91 M Decreased by -85.38% | Decreased by -233.85% Decreased by -335.70% |
| Mar 31, 25 | 4.13 M Decreased by -63.02% | -25.04 M Increased by +0.43% | Decreased by -606.71% Decreased by -169.22% |
| Dec 31, 24 | 9.61 M Decreased by -22.46% | -23.40 M Decreased by -21.27% | Decreased by -243.37% Decreased by -56.40% |
| Sep 30, 24 | 11.51 M Decreased by -6.87% | -18.77 M Increased by +5.28% | Decreased by -163.04% Decreased by -1.70% |
| Jun 30, 24 | 20.01 M Increased by +76.48% | -10.74 M Increased by +17.44% | Decreased by -53.67% Increased by +53.22% |
| Mar 31, 24 | 11.16 M Increased by +28.90% | -25.15 M Decreased by -55.88% | Decreased by -225.36% Decreased by -20.93% |
| Dec 31, 23 | 12.40 M Increased by +121.61% | -19.29 M Decreased by -31.91% | Decreased by -155.61% Increased by +40.48% |